Novocure Announces Optune Now Available at more than 150 Leading Cancer Centers across the United States December 19, 2014
Novocure Announces FDA Approval of an IDE Supplement Allowing All Control Patients in its Phase III Trial in Newly Diagnosed GBM to Cross Over to Receive Tumor Treating Fields December 02, 2014
Interim Analysis of Novocure’s Phase III Trial in Newly Diagnosed Glioblastoma to be Presented at Japan Society For Neuro-Oncology 2014 December 01, 2014
Novocure Announces the EF-14 Phase III Clinical Trial of Tumor Treating Fields in Patients with Newly Diagnosed Glioblastoma has been Terminated at the Interim Analysis due to Early Success November 15, 2014
Novocure Announces the Presentation of New Data at the 19th Annual Society of Neuro-Oncology Meeting November 11, 2014
Novocure Enrolls First Patient in a Pilot Study of Tumor Treating Fields Together with Paclitaxel for the Treatment of Recurrent Ovarian Cancer October 30, 2014
Novocure Announces Publication of a NovoTTF Therapy Supplement in Seminars in Oncology including Analyses of its U.S. Commercial Patient Registry Dataset (PRiDe) October 29, 2014
Novocure™ Announces Recurrent Glioblastoma Patient Registry Dataset (PRiDe) to be Presented at ESMO and EANO 2014 September 25, 2014
